Pharma Equity Group A/S (PEG.CO)
DKK 0.18
(-2.17%)
DKK 0.18
(-2.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -25.29 Million DKK | -491.65% |
| 2022 | -4.27 Million DKK | -196.05% |
| 2021 | -1.44 Million DKK | 32.37% |
| 2020 | -2.13 Million DKK | -27.77% |
| 2019 | -1.67 Million DKK | 0.12% |
| 2018 | -1.67 Million DKK | 15.63% |
| 2017 | -1.98 Million DKK | -12.93% |
| 2016 | -1.75 Million DKK | 43.15% |
| 2015 | -3.08 Million DKK | -54.22% |
| 2014 | -2 Million DKK | 61.77% |
| 2013 | -5.23 Million DKK | -10.29% |
| 2012 | -4.75 Million DKK | -418.36% |
| 2011 | 1.49 Million DKK | -55.91% |
| 2010 | 3.38 Million DKK | 466.23% |
| 2009 | -924 Thousand DKK | 99.0% |
| 2008 | -92.66 Million DKK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.82 Million DKK | 0.25% |
| 2024 Q2 | -4.98 Million DKK | 26.95% |
| 2023 Q4 | -6.84 Million DKK | -19.75% |
| 2023 Q1 | -3.39 Million DKK | -188.09% |
| 2023 Q2 | -4.93 Million DKK | -45.33% |
| 2023 Q3 | -5.71 Million DKK | -15.85% |
| 2023 FY | -25.29 Million DKK | -491.65% |
| 2022 Q4 | 3.85 Million DKK | 239.44% |
| 2022 FY | -4.27 Million DKK | -196.05% |
| 2022 Q2 | -2886.00 DKK | 0.0% |
| 2022 Q3 | -2.76 Million DKK | -95672.7% |
| 2021 FY | -1.44 Million DKK | 32.37% |
| 2020 FY | -2.13 Million DKK | -27.77% |
| 2019 FY | -1.67 Million DKK | 0.12% |
| 2018 FY | -1.67 Million DKK | 15.63% |
| 2017 FY | -1.98 Million DKK | -12.93% |
| 2016 Q1 | -371 Thousand DKK | 78.96% |
| 2016 FY | -1.75 Million DKK | 43.15% |
| 2016 Q2 | -210 Thousand DKK | 43.4% |
| 2015 FY | -3.08 Million DKK | -54.22% |
| 2015 Q4 | -1.76 Million DKK | -112.67% |
| 2015 Q3 | -829 Thousand DKK | -71.64% |
| 2015 Q2 | -483 Thousand DKK | -34.54% |
| 2015 Q1 | -359 Thousand DKK | 50.75% |
| 2014 Q4 | -729 Thousand DKK | -483.2% |
| 2014 Q1 | -189 Thousand DKK | 99.84% |
| 2014 FY | -2 Million DKK | 61.77% |
| 2014 Q2 | -761 Thousand DKK | -302.65% |
| 2014 Q3 | -125 Thousand DKK | 83.57% |
| 2013 Q2 | 20.03 Million DKK | 1919.71% |
| 2013 Q4 | -115.08 Million DKK | -4257.59% |
| 2013 Q3 | -2.64 Million DKK | -113.18% |
| 2013 Q1 | -1.1 Million DKK | -31.86% |
| 2013 FY | -5.23 Million DKK | -10.29% |
| 2012 Q3 | -210 Thousand DKK | -176.64% |
| 2012 Q2 | 274 Thousand DKK | -72.68% |
| 2012 FY | -4.75 Million DKK | -418.36% |
| 2012 Q1 | 1 Million DKK | -75.42% |
| 2012 Q4 | -835 Thousand DKK | -297.62% |
| 2011 Q2 | -137 Thousand DKK | -113.37% |
| 2011 Q3 | 508 Thousand DKK | 470.8% |
| 2011 FY | 1.49 Million DKK | -55.91% |
| 2011 Q1 | 1.02 Million DKK | -83.72% |
| 2011 Q4 | 4.08 Million DKK | 703.15% |
| 2010 FY | 3.38 Million DKK | 466.23% |
| 2010 Q4 | 6.29 Million DKK | 515.03% |
| 2010 Q3 | -1.51 Million DKK | -8.82% |
| 2010 Q2 | -1.39 Million DKK | -300.57% |
| 2010 Q1 | -348 Thousand DKK | 62.34% |
| 2009 Q2 | -4.24 Million DKK | 0.0% |
| 2009 Q3 | -60 Thousand DKK | 98.59% |
| 2009 FY | -924 Thousand DKK | 99.0% |
| 2009 Q4 | -924 Thousand DKK | -1440.0% |
| 2008 FY | -92.66 Million DKK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ALK-Abelló A/S | 666 Million DKK | 103.798% |
| Bavarian Nordic A/S | 1.49 Billion DKK | 101.689% |
| Genmab A/S | 5.32 Billion DKK | 100.475% |
| Gubra A/S | -49.41 Million DKK | 48.817% |
| Novo Nordisk A/S | 102.57 Billion DKK | 100.025% |
| Orphazyme A/S | -27.04 Thousand DKK | -93435.742% |
| Zealand Pharma A/S | -572.23 Million DKK | 95.58% |